National UK guidelines for the management of paediatric craniopharyngioma

Lancet Diabetes Endocrinol. 2023 Sep;11(9):694-706. doi: 10.1016/S2213-8587(23)00162-6. Epub 2023 Aug 4.


Although rare, craniopharyngiomas constitute up to 80% of tumours in the hypothalamic-pituitary region in childhood. Despite being benign, the close proximity of these tumours to the visual pathways, hypothalamus, and pituitary gland means that both treatment of the tumour and the tumour itself can cause pronounced long-term neuroendocrine morbidity against a background of high overall survival. To date, the optimal management strategy for these tumours remains undefined, with practice varying between centres. In light of these discrepancies, as part of a national endeavour to create evidence-based and consensus-based guidance for the management of rare paediatric endocrine tumours in the UK, we aimed to develop guidelines, which are presented in this Review. These guidelines were developed under the auspices of the UK Children's Cancer and Leukaemia Group and the British Society for Paediatric Endocrinology and Diabetes, with the oversight and endorsement of the Royal College of Paediatrics and Child Health using Appraisal of Guidelines for Research & Evaluation II methodology to standardise care for children and young people with craniopharyngiomas.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Craniopharyngioma* / diagnosis
  • Craniopharyngioma* / therapy
  • Humans
  • Hypothalamus
  • Morbidity
  • Pituitary Neoplasms* / diagnosis
  • Pituitary Neoplasms* / therapy
  • United Kingdom